IMMX

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Immix Biopharma reports an 89% complete response rate in an interim analysis of all NEXICART-2 patients, with MRD negativity indicating a potential rate of up to 98%Sep 29, 2026
• Immix Biopharma reports 95% complete response rate in interim NEXICART-2 amyloidosis trial updateMay 21, 2026
• Immix Biopharma completed enrollment in its BLA-enabling NEXICART-2 trial for relapsed or refractory AL amyloidosisMar 30, 2026
• Immix Biopharma received FDA Breakthrough Therapy Designation for NXC-201Jan 28, 2026
• Immix Biopharma announces 50% enrollment milestone surpassed in ongoing relapsed/refractory AL amyloidosis clinical trial, NEXICART-2Sep 19, 2025